Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 20.8x which is lower than its 3-year average PE of 25.5x. The industry is trading close to its 3-year average PS ratio of 3.4x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 25 May 2026	UK£328.4b	UK£91.9b	UK£15.8b	18.3x	20.8x	3.6x
Wed, 22 Apr 2026	UK£346.3b	UK£90.4b	UK£15.5b	18.8x	22.3x	3.8x
Fri, 20 Mar 2026	UK£335.7b	UK£90.5b	UK£15.6b	21.6x	21.5x	3.7x
Sun, 15 Feb 2026	UK£363.5b	UK£89.7b	UK£15.3b	24.1x	23.7x	4.1x
Tue, 13 Jan 2026	UK£332.3b	UK£89.4b	UK£14.6b	21.2x	22.8x	3.7x
Thu, 11 Dec 2025	UK£319.1b	UK£89.8b	UK£14.7b	20.8x	21.8x	3.6x
Sat, 08 Nov 2025	UK£309.0b	UK£90.4b	UK£14.8b	21.1x	20.9x	3.4x
Mon, 06 Oct 2025	UK£297.8b	UK£87.6b	UK£11.7b	19.4x	25.5x	3.4x
Wed, 03 Sep 2025	UK£281.4b	UK£87.9b	UK£11.8b	21.6x	23.9x	3.2x
Fri, 01 Aug 2025	UK£272.2b	UK£88.7b	UK£11.4b	28.4x	23.8x	3.1x
Sun, 29 Jun 2025	UK£256.1b	UK£85.8b	UK£10.5b	25.8x	24.3x	3x
Tue, 27 May 2025	UK£263.4b	UK£86.2b	UK£10.6b	27x	24.9x	3.1x
Thu, 24 Apr 2025	UK£257.7b	UK£86.6b	UK£9.6b	27.1x	26.9x	3x
Sat, 22 Mar 2025	UK£284.4b	UK£87.8b	UK£9.7b	32.7x	29.4x	3.2x
Mon, 17 Feb 2025	UK£282.8b	UK£88.9b	UK£9.5b	30.6x	29.9x	3.2x
Wed, 15 Jan 2025	UK£225.2b	UK£76.7b	UK£7.9b	30.9x	28.4x	2.9x
Fri, 13 Dec 2024	UK£225.7b	UK£74.9b	UK£7.7b	32.1x	29.3x	3x
Sun, 10 Nov 2024	UK£217.2b	UK£72.6b	UK£7.6b	30.7x	28.6x	3x
Tue, 08 Oct 2024	UK£251.2b	UK£72.2b	UK£9.0b	31.1x	27.8x	3.5x
Thu, 05 Sep 2024	UK£277.7b	UK£72.0b	UK£9.0b	41.3x	31x	3.9x
Sat, 03 Aug 2024	UK£266.8b	UK£72.9b	UK£9.0b	38.9x	29.6x	3.7x
Mon, 01 Jul 2024	UK£261.5b	UK£71.8b	UK£9.6b	29.6x	27.3x	3.6x
Wed, 29 May 2024	UK£265.2b	UK£71.4b	UK£9.5b	32.4x	27.8x	3.7x
Fri, 26 Apr 2024	UK£261.0b	UK£71.7b	UK£10.1b	32.2x	26x	3.6x
Sun, 24 Mar 2024	UK£240.9b	UK£70.9b	UK£9.8b	31.3x	24.7x	3.4x
Tue, 20 Feb 2024	UK£236.5b	UK£69.8b	UK£9.6b	36x	24.6x	3.4x
Thu, 18 Jan 2024	UK£237.7b	UK£69.0b	UK£10.7b	36.3x	22.3x	3.4x
Sat, 16 Dec 2023	UK£227.4b	UK£69.0b	UK£10.7b	33.9x	21.3x	3.3x
Mon, 13 Nov 2023	UK£224.7b	UK£70.4b	UK£10.9b	53x	20.7x	3.2x
Wed, 11 Oct 2023	UK£246.2b	UK£70.3b	UK£10.4b	74.9x	23.7x	3.5x
Fri, 08 Sep 2023	UK£238.4b	UK£69.7b	UK£10.3b	53.5x	23.3x	3.4x
Sun, 06 Aug 2023	UK£238.4b	UK£68.9b	UK£10.2b	52.8x	23.5x	3.5x
Tue, 04 Jul 2023	UK£230.5b	UK£67.8b	UK£7.9b	55.1x	29.2x	3.4x
Thu, 01 Jun 2023	UK£247.8b	UK£68.7b	UK£8.0b	55.5x	31x	3.6x


GB Market	1.53%
Healthcare	1.59%
Pharma	1.64%
Pharma	1.64%

Company	Last Price	7D	1Y	Valuation
AZN AstraZeneca	UK£139.16	1.5% +UK£3.2b	33.3%	PE27.9x
GSK GSK	UK£19.15	2.1% +UK£1.5b	34.3%	PE13.1x
HLN Haleon	UK£3.44	2.0% +UK£593.6m	-16.5%	PE18.3x
HIK Hikma Pharmaceuticals	UK£14.59	1.0% +UK£30.1m	-29.7%	PE10.5x
POLB Poolbeg Pharma	UK£0.05	6.1% +UK£2.0m	105.7%	PB4.1x

Announcement • May 23

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Daiichi Sankyo and AstraZeneca’s Datroway was approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval follows Priority Review by the U.S. Food and Drug Administration (FDA) based on results from the TROPION-Breast02 phase 3 trial which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. In the trial, Datroway demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival (OS) versus investigator’s choice of chemotherapy (hazard ratio [HR]=0.79; 95% confidence interval [CI]: 0.64-0.98; p=0.0290). Median OS was 23.7 months for patients treated with Datroway versus 18.7 months for those treated with chemotherapy. Datroway reduced the risk of disease progression or death by 43% compared to chemotherapy (HR=0.57; 95% CI: 0.47-0.69). This application was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, reviews are ongoing in Australia, Canada, Singapore and Switzerland. Additional reviews are underway in the EU, China and Japan. Based on the results of TROPION-Breast02, datopotamab deruxtecan-dlnk (Datroway) has been included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a Category 1 Preferred first-line treatment option for patients with metastatic TNBC who are not candidates for immunotherapy. Daiichi Sankyo and AstraZeneca are committed to ensuring that patients in the U.S. who are prescribed Datroway can access the medication and receive necessary financial support. Provider and patient support, reimbursement and distribution for Datroway in the U.S. will be accessible by visiting www.Datroway4U.com or calling 1-855-Datro4U (1-855-328-7648). Please visit www.Datroway.com for full Prescribing Information, including the Medication Guide. TROPION-Breast02 is a global, multicenter, randomized, open-label phase 3 trial evaluating the efficacy and safety of Datroway versus investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin or eribulin) in patients with previously untreated locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. This included patients whose tumors did not express PD-L1 as well as patients with PD-L1 expressing tumors who could not receive immunotherapy due to prior exposure in early-stage disease, comorbidities or immunotherapy not being accessible in their geography. Enrollment included patients with de novo or recurrent disease, regardless of disease-free interval, and those with poor prognostic factors such as stable brain metastases. The dual primary endpoints of TROPION-Breast02 are PFS as assessed by BICR and OS. Secondary endpoints include PFS as assessed by investigator, ORR, duration of response, disease control rate, pharmacokinetics and safety. TROPION-Breast02 enrolled 644 patients at sites in Africa, Asia, Europe, North America and South America. Datroway (datopotamab deruxtecan; datopotamab deruxtecan-dlnk in the U.S. only) is a TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Datroway is one of seven DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datroway is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Datroway (6 mg/kg) is approved in more than 40 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HR positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease based on the results from the TROPION-Breast01 trial. Datroway (6 mg/kg) is approved in Brazil, Russia and the U.S. for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, based on the results from the TROPION-Breast02 trial. Datroway (6 mg/kg) is approved in Russia and the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy, based on the results from TROPION-Lung05 and TROPION-Lung01 trials. Continued approval for this indication in the U.S. may be contingent upon verification and description of clinical benefit in a confirmatory trial. A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of Datroway across multiple cancers, including NSCLC, TNBC and urothelial cancer. The program includes eight phase 3 trials in lung cancer, five phase 3 trials in breast cancer, and one phase 3 trial and one phase 2/3 trial in urothelial cancer evaluating Datroway as a monotherapy and in combination with other cancer treatments in various settings. DATROWAY (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Innovent Biologics And HUTCHMED Jointly Announce NMPA Approval For TYVYT (Sintilimab Injection) In Combination With ELUNATE (Fruquintinib) For The Treatment Of Patients With Locally Advanced Or Metastatic Renal Cell Carcinoma

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

GSK plc to Report Q3, 2026 Results on Oct 28, 2026

STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside

HIK: Buyback And Index Move Will Support Future Re Rating

Poolbeg Pharma Receives Patent Grant For POLB 001 Cancer Immunotherapy-Induced CRS In Canada

HLN: Cash Returns And China Expansion Will Support Future Premium Re Rating

New major risk - Share price stability

Eco Animal Health Group plc Announces Appointment of Andrew Winder as Head of Business Development, Effective May 11, 2026

New major risk - Share price stability

First half 2026 earnings released: UK£0.004 loss per share (vs UK£0.002 loss in 1H 2025)

New major risk - Shareholder dilution

New major risk - Financial position